Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 9 pages · English
Earlier from LTR Pharma
- First Patients Dosed in SPONTAN Phase II Clinical Study
- TGA Provides Regulatory Clearance for SPONTAN Phase II
- Ethics Approval Received for SPONTAN Phase II Clinical Study
- LTR increases LevOmega stake to 43% with $1m investment
- LTR Pharma secures 33% ownership in LevOmega Pty Ltd
Later from LTR Pharma
- SPONTAN Shows Positive Outcomes in Younger Men with ED
- Appendix 4D and Half Yearly Report
- SPONTAN Phase II Clinical Study Completes Recruitment
- SPONTAN Phase II data show rapid onset, support FDA pathway
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma